- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeremy Whalen Cites Patient Safety, Total Cost of Care as Key Policy Goals for Prime Therapeutics
Patient safety is paramount when deciding how to roll out a new program or even if a program should be developed or not, said Jeremy Whalen, PharmD, BCOP, specialty clinical program director for oncology at Prime Therapeutics.
Patient safety is paramount when deciding how to roll out a new program or even if a program should be developed or not. After that, the consideration would be what impact the program will have on total cost of care for that member, said Jeremy Whalen, PharmD, BCOP, specialty clinical program director for oncology at Prime Therapeutics.
Transcript
How has cost-effectiveness impacted medication prescriptions as healthcare transitions to a more value-based model?
Costs will still be a driver within a value-based care model, and I think it’ll become a bigger component of it. As providers are more engaged within what the cost of care is, and they're having those conversations with the patients up front—that now is becoming a part of the decision on what care is being delivered. When we have equally efficacious or similarly efficacious medications or regimens to treat the patient, cost will now be kind of a driving factor in a value-based model on what therapies patients receive.
What are the various benchmarks that decision makers consider when deciding whether to implement or test certain strategies or policies?
Patient Safety is kind of paramount when we're deciding how to roll out a new program or even if a program should be developed or not. After that, it [would] really be also what impact the program will have on total cost of care for that member—will it increase it? Will it decrease it? Then, also I kind of say tongue-in-cheek is will this program get us on the Wall Street Journal? Will that be a positive thing or a negative thing on that front page?
As we look at oncology and the cost within that system, the total cost of care is really becoming paramount. One thing that we're really striving and are successful with at Prime Therapeutics is doing integration of health and benefits. So, both on the medical and pharmacy side, to really look at what that impact is on the patient and that total cost so then we can help make better decisions and support our patients.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
